Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2026 17:15 ET | Source: Iovance Biotherapeutics, Inc.

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel...
March 05, 2025 07:00 ET | Source: KSQ

KSQ Therapeutics Appoints Kristen Hege, M.D., to its Board of Directors

KSQ Therapeutics Appoints Kristen Hege, M.D., to its Board of Directors
October 08, 2024 07:00 ET | Source: KSQ

KSQ Therapeutics Appoints Anna Truppel-Hartmann, M.D., as Chief Medical Officer

KSQ Therapeutics Appoints Anna Truppel-Hartmann, M.D., as Chief Medical Officer
August 14, 2024 07:00 ET | Source: Achilles Therapeutics PLC

Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates

– Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles’ AI-powered, tumor-targeting technology – – Provided interim Phase I/IIa...
July 08, 2024 20:00 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc., announces presentation of data on induction of tumor growth inhibiting anti-cancer immune responses in multiple types of cancers by a IRX5010, a novel retinoic acid nuclear receptor agonist compound

Io Therapeutics, Inc presented studies in multiple cancers with its novel drug that inhibits tumor growth by promoting tumor infiltrating T-lymphocytes
June 12, 2024 07:00 ET | Source: KSQ

KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy

KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered eTIL® Therapy
November 09, 2023 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
December 29, 2022 21:02 ET | Source: Bragar Eagel & Squire

INSTIL BIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Instil Bio, Inc. on Behalf of Instil Bio Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Instil Bio, Inc. (“Instil...
October 06, 2022 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors

Autologous TIL therapy enhanced with Lyell’s Epi-R™ reprogramming technology designed to create polyclonal T cell populations with properties of durable stemness and improved functionPhase 1 trial to...
November 09, 2021 08:00 ET | Source: Achilles Therapeutics PLC

Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights

- Oral Presentation at European Society for Gene and Cell Therapy (ESGCT) demonstrated ability to generate potent anti-cancer cell therapy candidates in multiple solid tumor types - - Society for...